原发性脑瘤患者的抑郁药物治疗有获益吗？Cochrane 综述总结与述评。
Does pharmacological treatment of depression in people with a primary brain tumour bring any benefits? A Cochrane Review summary with commentary.
机构信息
Department of Rehabilitation Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
出版信息
NeuroRehabilitation. 2022;50(4):501-503. doi: 10.3233/NRE-228019.
BACKGROUND
Persons with primary brain tumour can suffer from depression. Depression may hinder rehabilitation intervention leading to further deterioration of patient's health and functioning.
OBJECTIVE
The Cochrane Review aimed to assess the effectiveness and adverse effects of pharmacological treatment of depression in people with a primary brain tumour.
METHODS
A Cochrane Review by Beevers et al. was summarized with comments.
RESULTS
The review did not find any eligible studies from the 2090 studies screened which included randomized controlled trials, cohort studies and case-control studies.
CONCLUSIONS
There is no high-quality evidence as to whether pharmacological treatments for depression in people with primary brain tumours are either effective or harmful.
背景
原发性脑肿瘤患者可能会患有抑郁症。抑郁症可能会阻碍康复干预，从而导致患者的健康和功能进一步恶化。
目的
本 Cochrane 综述旨在评估针对原发性脑肿瘤患者的药物治疗抑郁症的效果和不良反应。
方法
对 Beevers 等人的 Cochrane 综述进行了总结并添加了评论。
结果
对 2090 项筛选出的研究（包括随机对照试验、队列研究和病例对照研究）进行综述后，并未发现任何符合条件的研究。
结论
针对原发性脑肿瘤患者的抑郁症的药物治疗是否有效或有害，尚无高质量证据。
Zotero 插件